This randomized controlled trial demonstrated that intravenous parecoxib significantly reduces the incidence of post-ERCP pancreatitis (PEP) compared to standard hydration alone. The study highlights the potential of parecoxib as an effective prophylactic agent in preventing PEP, especially in settings where rectal NSAIDs are unavailable.
Background
Endoscopic retrograde cholangiopancreatography (ERCP) is a key therapeutic procedure for pancreatobiliary diseases but carries risks including post-ERCP pancreatitis (PEP), which occurs in 3.5–14.7% of cases and can be fatal. Current preventive strategies include rectal NSAIDs, aggressive hydration, and other pharmacologic agents. Parecoxib, a selective COX-2 inhibitor administered intravenously, offers rapid onset and predictable absorption, making it a promising alternative for PEP prevention, particularly where rectal NSAIDs are not accessible.
Data Highlights
Outcome
Parecoxib Group
Control Group
Significance
Incidence of PEP
Significantly lower
Higher incidence
p-value not specified
Post-ERCP abdominal pain
Reduced
Higher
Not specified
Adverse events
No serious events reported
Not specified
Not specified
Key Findings
Intravenous parecoxib administered before ERCP significantly reduces the incidence of PEP compared to standard hydration alone.
Parecoxib provides rapid analgesic effects, with peak action occurring within 2 hours, beneficial for post-ERCP pain control.
The pharmacokinetic profile of intravenous parecoxib offers more predictable absorption than rectal NSAIDs, which can be affected by stool presence.
No serious adverse events related to parecoxib were reported, indicating a favorable safety profile.
Patients classified as high risk for PEP may particularly benefit from parecoxib prophylaxis.
Clinical Implications
Intravenous parecoxib represents a viable prophylactic option to reduce PEP incidence, especially in clinical settings lacking access to rectal NSAIDs. Its rapid onset and predictable pharmacokinetics make it suitable for pre-ERCP administration, potentially improving patient outcomes and reducing hospitalization related to PEP.
Conclusion
This study supports intravenous parecoxib as an effective and safe intervention to prevent post-ERCP pancreatitis, offering an alternative to rectal NSAIDs. Incorporation of parecoxib into clinical practice may enhance PEP prophylaxis strategies.
References
European Society of Gastrointestinal Endoscopy (ESGE) 2020 -- PEP Definition and Guidelines
Meta-analyses on Rectal NSAIDs -- Efficacy in PEP Prevention
Pharmacokinetics of Parecoxib -- Rapid Onset and Half-life
Randomized Controlled Trial of Intravenous Parecoxib -- Post-ERCP Pain Reduction
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
